VERA President and CEO Fordyce Marshall sells ~18,500 shares for $680K as stock trades well below its 52-week high; all five prior VERA sales saw subsequent declines.
Fordyce Marshall, President and CEO of Vera Therapeutics, is liquidating equity with this sale of approximately 18,500 shares, reducing his stake by roughly 8%. The stock is currently trading well below its 52-week high, having declined over the recent quarter, while the company remains unprofitable with significant operating losses. What makes this sale notable is Marshall's own track record at this company: all five of his prior open-market sales at Vera have been followed by stock declines, suggesting he has demonstrated consistent skill at timing exits before downward pressure. This is his sixth and seventh open-market sale at Vera in the past three years, continuing a pattern of steady, well-timed dispositions rather than panic selling or one-off exits. However, the underlying fundamentals remain weak—the company is not profitable, and the cumulative losses suggest significant operational challenges ahead.